Skip to content

Vertex Pharmaceuticals

US · VRTX #155 by market cap Listed 1970
515.02 -5.64 -1.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $620 From $608
    MT Newswires · 2026/11/4
  • Rating change
    A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $563 to $725
    Market Newswire · 2026/11/4
  • Company notice
    Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/17
  • Rating change
    Vertex Pharmaceuticals Price Target Raised to $626.00/Share From $617.00 by Barclays
    Dow Jones · 2026/11/5
  • RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600
    Market Newswire · 2026/11/18
  • Company notice
    Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thornberry Nancy
    SEC · 2026/11/19
  • Rating change
    Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $640 From $556
    MT Newswires · 2026/11/10
  • Rating change
    Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $620
    Market Newswire · 2026/11/5
  • Rating change
    Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $620
    Market Newswire · 2026/11/5
  • Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
    Benzinga · 2026/11/14
  • Rating change
    UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $640
    Market Newswire · 2026/11/4
  • Company notice
    Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/16
  • Company notice
    Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer WAGNER CHARLES F JR
    SEC · 2026/11/17
  • Vertex Pharmaceuticals(VRTX.US) Officer Sells US$8.37 Million in Common Stock
    Market Newswire · 2026/11/17
  • Company notice
    Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bhatia Sangeeta N.
    SEC · 2026/11/19
  • Rating change
    Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $626
    Benzinga · 2026/11/5
  • Rating change
    Vertex Pharmaceuticals Price Target Raised to $570.00/Share From $560.00 by JP Morgan
    Dow Jones · 2026/11/4
  • BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
    Market Newswire · 2026/11/12
  • Rating change
    Vertex Pharmaceuticals Is Maintained at Overweight by Barclays
    Dow Jones · 2026/11/5
  • H.C. Wainwright Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $641
    Market Newswire · 2026/11/20
  • Company notice
    Vertex Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- Brennan Daniel J.
    SEC · 2026/10/23
  • Rating change
    Vertex Pharmaceuticals Price Target Cut to $660.00/Share From $665.00 by Morgan Stanley
    Dow Jones · 2026/11/4
  • Rating change
    Vertex Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
    Dow Jones · 2026/11/4
  • Company notice
    Vertex Pharmaceuticals | 8-K: Vertex Reports Third Quarter 2026 Financial Results
    SEC · 2026/11/3
  • Rating change
    Vertex Pharmaceuticals Price Target Raised to $725.00/Share From $654.00 by Goldman Sachs
    Dow Jones · 2026/11/4

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.

Vertex Pharmaceuticals discussion 0 comments

Add a comment